Automate Your Wheel Strategy on SNY
With Tiblio's Option Bot, you can configure your own wheel strategy including SNY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SNY
- Rev/Share 17.2983
- Book/Share 30.1835
- PB 1.3648
- Debt/Equity 0.2969
- CurrentRatio 1.0603
- ROIC 0.0612
- MktCap 99997083914.2926
- FreeCF/Share 0.8591
- PFCF 47.7769
- PE 10.9724
- Debt/Assets 0.1676
- DivYield 0.046
- ROE 0.1236
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | SNY | Guggenheim | Buy | Neutral | -- | -- | Dec. 9, 2025 |
| Downgrade | SNY | JP Morgan | Overweight | Neutral | -- | -- | Dec. 8, 2025 |
| Upgrade | SNY | Morgan Stanley | Equal Weight | Overweight | -- | $58 | Sept. 8, 2025 |
| Upgrade | SNY | Deutsche Bank | Hold | Buy | -- | -- | Sept. 2, 2025 |
| Upgrade | SNY | JP Morgan | Neutral | Overweight | -- | -- | Aug. 8, 2025 |
| Initiation | SNY | Exane BNP Paribas | -- | Outperform | -- | $65 | April 15, 2025 |
| Initiation | SNY | Goldman | -- | Neutral | -- | $65 | March 21, 2025 |
| Upgrade | SNY | Deutsche Bank | Sell | Hold | -- | -- | Jan. 30, 2025 |
News
Press Release: Availability of the Q1 2025 Aide mémoire
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Availability of the Q1 2025 Aide mémoire Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website: First quarter 2025 (sanofi.com) As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results.
Read More
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company.
Read More
Sanofi to acquire Dren Bio's immunology unit
Published: March 20, 2025 by: Reuters
Sentiment: Positive
Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.
Read More
Press Release: Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front Paris, March 20, 2025. Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies.
Read More
Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
Published: March 14, 2025 by: PRNewsWire
Sentiment: Neutral
BRIDGEWATER, N.J. , March 14, 2025 /PRNewswire/ -- Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025-26 flu season in the US.
Read More
Sanofi Stock Forms Golden Cross As Dupixent Eyes FDA Green Light: Can The Bullish Run Continue?
Published: March 12, 2025 by: Benzinga
Sentiment: Positive
Sanofi NV SNY has been flexing its biotech muscles, and investors are taking notice. The stock is firmly in bullish territory, recently forming a Golden Cross , a classic technical signal that often precedes further gains.
Read More
Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from the IMROZ phase 3 study that demonstrated Sarclisa in combination with VRd significantly improved progression-free survival, compared to VRd alone in transplant-ineligible newly diagnosed multiple myeloma Paris, February 25, 2025. The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) based on data from the IMROZ phase 3 …
Read More
Press Release: Sanofi and CD&R sign Opella share purchase agreement
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi and CD&R sign Opella share purchase agreement Paris, February 19, 2025 . Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed the share purchase agreement in relation to the sale of a 50% controlling stake in Opella to CD&R.
Read More
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
Published: February 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.
Read More
Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report Paris, February 13, 2025. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d'Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).
Read More
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient efficacy in preventing invasive E.
Read More
About Sanofi (SNY)
- IPO Date 2002-07-01
- Website https://www.sanofi.com
- Industry Drug Manufacturers - General
- CEO Paul Hudson
- Employees 82878